Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - PubMed

Eli Lilly and Company.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov